I suspect this popular medicine has been the target of a discrediting campaign for the simple reason it competes with newer, far more expensive blood thinners and pain relievers that cost 366 times more. Studies show it’s just as effective, and the only difference is cost. STORY AT-A-GLANCE For decades, a daily regimen of low-dose so-called “baby aspirin” (81 mg), was recommended to prevent and treat heart attack, stroke and angina (chest pain) in those 50 and older.
That began to change in 2014, when the U.S. Food and Drug Administration started warning against the use of aspirin as a primary preventive for these conditions. In late 2021, the U. S. Preventive Services Task Force also updated its guidance to formally discourage people 60 and older from using an aspirin regimen to prevent a first heart attack or stroke.
Aspirin is likely the victim of an intentional pharma discrediting campaign to justify and promote the use of newer, patented, and far more expensive nonsteroidal anti-inflammatory drugs and anticoagulants.
Research has shown aspirin works just as well as pricier anticoagulants such as heparin and Xarelto for preventing post-operative blood clots and clots associated with bone fractures.
Aspirin also increases the oxidation of glucose as fuel, and has anti-lipolytic effects, so it helps lower both the supply of dangerous omega-6 fat to your cells and the excessive oxidation of fats. Aspirin will also lower your baseline cortisol, indirectly by lowering inflammation, and directly by inhibiting the enzyme that synthesizes active cortisol from the inactive precursor cortisone. There are many instances in which a perfectly safe and effective medicine has become the target of an unjustified discrediting campaign in order to push newer patented (and hence profitable) drugs to the forefront. Ivermectin and hydroxychloroquine are by now two well-known examples. Long before that, however, there was a concerted effort to discredit aspirin….